



POLICY AND PROCEDURE

POLICY NUMBER: *RX.PA.017.E*

REVISION DATE: *7/15*

PAGE NUMBER: 1 of 3

POLICY TITLE: Celebrex (Celecoxib) Step Therapy
DEPARTMENT: Clinical Pharmacy Services- Utilization Management
ORIGINAL DATE: April 1999 (as adopted from UPMC Health Plan)

Last P & T Committee Approval Date: February 2018

Product Applicability: mark all applicable products below:

COMMERCIAL	<input type="checkbox"/> HMO <input type="checkbox"/> PPO Products: <input type="checkbox"/> Small Exchange: <input type="checkbox"/> Shop <input checked="" type="checkbox"/> All <input type="checkbox"/> Indiv. <input type="checkbox"/> Indiv. <input type="checkbox"/> Large
OTHER	<input checked="" type="checkbox"/> Self-funded/ASO

PURPOSE

The purpose of this policy is to define the prior authorization process for Celebrex (celecoxib).

Celebrex (celecoxib) is a COX-2 (cyclooxygenase-2) selective inhibitor indicated for osteoarthritis, rheumatoid arthritis, acute pain, primary dysmenorrhea, ankylosing spondylitis, adenomatous colorectal polyps in familial adenomatous polyposis, and juvenile rheumatoid arthritis (JRA) in patients two years of age and older.

- In April 2005, the FDA added a black box warning to Non-steroidal Anti-inflammatory Drugs (NSAIDs) describing possible cardiovascular and gastrointestinal risks associated with its use.

DEFINITIONS

N/A

POLICY

It is the policy of the Health Plan to maintain a prior authorization process that promotes appropriate utilization of specific drugs with potential for misuse or limited indications. This process involves a review using Food and Drug Administration (FDA) criteria to make a determination of Medical Necessity, as defined in CRM.015-Medical Necessity, and approval by the Pharmacy & Therapeutics Committee of the criteria for prior authorization, as described in RX.003-Prior Authorization Process.

The drug, Celebrex (celecoxib), is subject to the prior authorization process.



Celebrex (Celecoxib) Step Therapy

POLICY NUMBER: RX.PA.017.E

REVISION DATE: 7/15

PAGE NUMBER: 2 of 3

PROCEDURE

Initial Authorization Criteria:

Must meet all of the criteria listed under the respective diagnosis:

1. The criteria for automatic coverage of celecoxib (Celebrex) are as follows:

- Must be at least 65 years of age **OR**
- Must have a documented pharmacy claim history of one of the following:
 - Anticoagulant or antiplatelet therapy
 - 2 prescription strength non-steroidal anti-inflammatory drugs (NSAIDs)

2. For members who do not meet the automatic coverage criteria, a medical necessity review is completed, and the following criteria must be met:

- Must have an FDA-approved diagnosis or have a compendia-supported indication for celecoxib (Celebrex)
- Must meet one of the following requirements:
 - History of GI bleed
 - Documented ulcer (peptic, duodenal or gastric)
 - Anticoagulant or antiplatelet use
 - Coagulopathy, active bleed, or bleeding disorder
 - Chronic steroid use
 - Documented trial and failure of 2 prescription strength NSAIDs

3. If the member does have a risk factor listed above, the prescribing physician must verify that the member is aware of possible gastrointestinal and cardiovascular risks associated with the use of Celebrex and the authorization is granted.

4. Celebrex is not approved if being used for the treatment of peri-operative pain in setting of coronary artery bypass graft (CABG) surgery.

Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	Up to duration of member's membership with plan
Reauthorization	N/A
Quantity Level Limit	
All Strengths	60 per month

If the established criteria are not met, the request is referred to a Medical Director for review.

REFERENCES

1. MacDonald TM. Epidemiology and pharmaco-economic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. *Rheumatology*. 2000; 39(Suppl 2):13-20.
2. Wolfe MM, Lichtenstein Dr, Singh G. Medical progress: Gastrointestinal toxicity on nonsteroidal anti-inflammatory drugs. *NEJM*. 1999; 340(24):1888-1899.



Celebrex (Celecoxib) Step Therapy

POLICY NUMBER: RX.PA.017.E

REVISION DATE: 7/15

PAGE NUMBER: 3 of 3

3. Schoenfeld P. An evidence-based approach to the gastrointestinal safety profile of Cox-2-selective anti-inflammatories. *Gastroent Clin.* 2001; 30(4):1027-1045.
4. Griffen MR, Piper JM, Daughtery JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk per peptic ulcer disease in elderly persons. *Ann Inter Med.* 1991; 114(4):257-63.
5. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the AD Hoc Committee on Practice Parameters of the American College of Gastroenterology. *Am J Gastroenterol.* 1998; 93(11):2037-46.
6. Twycross R, et al. The risks and benefits of corticosteroids in advanced cancer. *Drug Safety.* 1994; 11:163-178.
7. Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. *NEJM.* 1983; 309:21-24.
8. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. *J Clin Pharmacol.* 2000; 40(6):655-63.
9. Kivitz A, Eisen G, Zhao W, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in members with osteoarthritis. *J Fam Practice.* 2002; 51(6):530-7.
10. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory an upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. *JAMA.* 1999; 282(20):1921-8.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in members with rheumatoid arthritis (VIGOR). *NEJM.* 2000; 343(21):1520-28.
12. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial. *JAMA.* 2000; 284(10):1247-55.
13. Dequeker J, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. *Br. J Rheumatol.* 1998; 37:956-51.
14. Caldwell B, ALdington S, Weatherall M, et al. Risk of cardio vascular events and celecoxib: a systematic review and meta-analysis. *J R Soc Med* 2006; 99:132-140
15. Spektor G and Fuster V. Drug InsightL cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? *Cardiovascular Medicine.* June 2005; 2(6):290-300.
16. Celebrex [package insert]. New York, NY: Pfizer, INC; April 2012.

RECORD RETENTION

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>Annual Review</i>	<i>02/17, 02/18</i>

